5-Aza-CdR reverses pericyte-myofibroblast transition by inhibiting Epo gene promoter hypermethylation in rat primary renal myofibroblasts
10.3969/j.issn.1671-7856.2025.01.008
- VernacularTitle:5-Aza-CdR通过抑制大鼠原代肾肌成纤维细胞Epo基因启动子高甲基化逆转PMT
- Author:
Ling YUAN
1
;
Lei WANG
1
;
Peng CHENG
1
;
Qian JIANG
1
;
Xiaoxue CUI
1
Author Information
1. 天津市医药科学研究所,天津 300020
- Publication Type:Journal Article
- Keywords:
pericyte-myofibroblast transition;
EPO;
DNA methylation;
5-aza-2'-deoxycytidine;
DNA methyltransferase
- From:
Chinese Journal of Comparative Medicine
2025;35(1):79-85
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the effect of the demethylating agent 5-aza-2'-deoxycytidine(5-Aza-CdR)on pericyte-myofibroblast transition(PMT)in primary rat renal myofibroblasts.Methods Rat primary renal myofibroblasts were treated with 5-Aza-CdR 250 ng/mL for 72 h,and the degree of Epo promoter methylation was detected by pyrosequencing.Protein expression levels of α-smooth muscle actin(α-SMA),platelet-derived growth factor receptor-β(PDGFRβ)and DNA methyltransferase(Dnmt3a)were detected by immunofluorescence and Western blot,and erythropoietin(EPO)levels in the supernatant were detected.Results Compared with the control group,5-Aza-CdR treatment significantly decreased the expression of Dnmt3a and hypermethylation of the Epo promoter,and subsequently decreased the expression of α-SMA and the expression ratio of α-SMA to PDGFRβ in myofibroblasts.Meanwhile,5-Aza-CdR treatment increased the level of EPO in the cell supernatant.Conclusions 5-Aza-CdR can reverse PMT by inhibiting Epo promoter hypermethylation in primary renal myofibroblasts.
